Evaluation of Treatment of High riSk proLiferative Diabetic retinopathY With Intravitreal Aflibercept injectioN
Status:
Unknown status
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
To assess the safety and efficacy of intravitreal aflibercept injection in the regression of
retinal neovascularization secondary to high-risk PDR.
To characterize baseline/post-induction/maintenance levels of proinflammatory mediators in
patients with high-risk PDR